Ophthalmic adverse events under tofacitinib and baricitinib: Case analysis of the European Pharmacovigilance Database

Ophthalmic adverse events under tofacitinib and baricitinib: Case analysis of the European Pharmacovigilance Database

•Numerous ophthalmic events are observed with jak inhibitors.•10% of reported ophthalmic events are inflammatory ocular disorders.•The pathophysiology is not known, the hypotheses suggested are a direct effect of the JAK inhibitor, a damage associated with rheumatic disease or a paradoxical effect o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2023-01, Vol.90 (1), p.105483-105483, Article 105483
Hauptverfasser: Hecquet, Sophie, Valnet Rabier, Marie-Blanche, Lepelley, Marion, Verhoeven, Frank, Delbosc, Bernard, Avouac, Jérôme, Prati, Clément, Gauthier, Anne-Sophie, Wendling, Daniel
Format: Artikel
Sprache:eng
Schlagworte:
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid - drug therapy
Humans
Jak inhibitors
Keratitis
Ocular manifestations
Pharmacovigilance
Piperidines - adverse effects
Rheumatoid arthritis
Scleritis
Spondyloarthritis
Uveitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Numerous ophthalmic events are observed with jak inhibitors.•10% of reported ophthalmic events are inflammatory ocular disorders.•The pathophysiology is not known, the hypotheses suggested are a direct effect of the JAK inhibitor, a damage associated with rheumatic disease or a paradoxical effect of the JAK inhibitor.
ISSN:1297-319X
1778-7254
DOI:10.1016/j.jbspin.2022.105483